{"id":286,"date":"2020-06-06T06:29:37","date_gmt":"2020-06-06T06:29:37","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=286"},"modified":"2020-06-19T06:48:44","modified_gmt":"2020-06-19T06:48:44","slug":"5-june-2020-tocilizumab-45-reduction-in-the-hazard-of-death-despite-twice-the-frequency-of-superinfection","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/5-june-2020-tocilizumab-45-reduction-in-the-hazard-of-death-despite-twice-the-frequency-of-superinfection\/","title":{"rendered":"(5 June 2020) Tocilizumab-45% reduction in the hazard of death, despite twice the frequency of superinfection"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Tocilizumab for treatment of mechanically ventilated patients with COVID-19<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.29.20117358v1.full.pdf<\/p>\n<p class=\"\">In this observational cohort study, 154 patients were included, of whom 78 received tocilizumab and 76 did not. Median follow-up was 47 days (range 28-67). In IPTW-adjusted models, tocilizumab was associated with a 45% reduction in hazard of death [hazard ratio 0.55 (95% CI 0.33, 0.90)] and improved status on the ordinal outcome scale [odds ratio per 1-level increase: 0.59 (0.36, 0.95)]. Though tocilizumab was associated with an increased proportion of patients with superinfections (54% vs. 26%;<br \/>\np&lt;0.001), there was no difference in 28-day case fatality rate among tocilizumab-treated patients with versus without superinfection [22% vs. 15%; p=0.42]. In this cohort of mechanically ventilated COVID-19 patients, tocilizumab was associated with a decreased likelihood of death despite higher superinfection occurrence. Randomized controlled trials are urgently needed to confirm these findings.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab for treatment of mechanically ventilated patients with COVID-19 https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.29.20117358v1.full.pdf In this observational cohort study, 154 patients were included, of whom 78 received tocilizumab and 76 did not. Median follow-up was 47 days (range 28-67). In IPTW-adjusted models, tocilizumab was&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/5-june-2020-tocilizumab-45-reduction-in-the-hazard-of-death-despite-twice-the-frequency-of-superinfection\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(5 June 2020) Tocilizumab-45% reduction in the hazard of death, despite twice the frequency of superinfection&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/286"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=286"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/286\/revisions"}],"predecessor-version":[{"id":287,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/286\/revisions\/287"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}